Skip to main content

Home/ Pharmaceutical Laboratory/ Group items tagged merck

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
hamelinclara

Merck Serono choisit les biosimilaires avec Dr Reddy's : BioPharmAnalyses - 1 views

biopharmanalyses.fr/s-biosimilaires-avec-dr-reddys

Biopharmceutics Biosimilaires Biotechnologies

shared by hamelinclara on 07 Dec 12 - No Cached
  • Longtemps confiné à un nombre restreint d’acteurs spécialisés, le marché des biosimilaires est aujourd’hui en pleine expansion. Au moment où le principal marché pharmaceutique s’apprête à leur ouvrir ses portes avec la finalisation en cours aux Etats-Unis d’une réglementation sur les « follow-on biologics » – équivalent de la terminologie européenne biosimilaire – , la perte, dans les cinq prochaines années, des brevets de quelques uns des principaux blockbusters biotech, à l’image des  anticorps monoclonaux Mabthera® (rituximab), Herceptin® (trastuzumab) ou encore Remicade® (infliximab), a certes de quoi attiser les convoitises…
  • Sur ce marché qu’une étude récente de Frost&Sullivan estime à près de quatre milliards de $ en Europe en 2017, la compétition promet d’être rude.
  • Il s’agit notamment de Sandoz, Teva, Lonza, BiogenIdec, Samsung, Amgen, Hospira, Watson Pharmaceuticals, Baxter, Momenta Pharmaceuticals, Fujifilm, Kyowa Hakko Kirin, Daiichi Sankyo, Boehringer Ingelheim, Stada ou encore Gedeon Richter… et enfin, tout dernier en date, l’allemand Merck KGaA…
hamelinclara

Les labos ont peur des réseaux sociaux…ils ont tort ! | La Factory NPA - 0 views

www.lafactory-npa.fr/...es-reseaux-sociauxils-ont-tort

bohering sanofi jeux social_media ehealth novartis bayer merck pfizer

shared by hamelinclara on 22 Apr 13 - No Cached
  • ’innovation thérapeutique (5), 69% des Français se disent mal informés au sujet de ces avancées et 14% des personnes interrogées seulement mentionnaient l’industrie pharmaceutique dans ce domaine
  • Les efforts de R&D en sont un.
  • @Diabetes_Sanofi . Animé par quatre contributrices, il permet échanges et conseils pour mieux vivre le diabète. En France, la chaîne Rose (www.lachainerose.fr, @lachainerose) est un lieu de témoignages et de soutien pour les femmes touchées par le cancer du sein.
  • ...4 more annotations...
  • De nombreuses entreprises proposent toutefois des sites sur des thèmes spécifiques. Novartis, par exemple, a créé un espace sur la sclérose en plaque (www.sep-et-vous.fr), un autre service dédié à l’accompagnement aux proches des malades (http://www.prochedemalade.com/). Pfizer se positionne sur la prévention avec www.prévention-tabac.com, Merck sur l’accompagnement des couples confrontés aux problèmes de stérilité (www.desirer-un-enfant.fr). Bayer, de son côté, réussit à dédramatiser les problèmes d’érection avec www.leplaisirdanslapoche.com.
  • Sanofi, avec sa chaîne YouTube, a tenté une approche grand public avec des conseils et des recettes pour les diabétiques ou les personnes ayant un problème de cholestérol. Sans aller cependant au bout de la logique d’une offre éditoriale cohérente, ces reportages étant noyés au milieu de vidéos corporate et d’image. Mais tout cela reste de la communication avec des témoignages balisés, où le partage et la conversation sont absents. Difficile dans u
  • Demain, l’innovation dans l’industrie pharmaceutique ne devra sans doute plus seulement être dans les produits, mais dans la communication et les services.
  • Valérie Van Oost
hamelinclara

DALLAS, Feb. 8. 2013: Pharmaceutical Market & Biotechnology Industry 2013 Outlook in Ne... - 0 views

www.heraldonline.com/...ical-market-biotechnology.html

biotechnology pharmaceutical

shared by hamelinclara on 13 Feb 13 - No Cached
  • Key Topics Covered Value Based Pricing- Strength of Innovation Vs Fiscal Pressures Major therapy areas to shape up pharma business going forward Europe – Regulatory Pressures and Increasing Pro Generic Stance Will US fall to Pricing Pressures? Emerging Markets and their importance in Growth of Large Cap Pharma Global Pharma -Drugs Losing Patent Protection By 2017 Impact of patent expiry in w.r.t. 2012 total revenue thru 2017 Global Pharma Research Pipeline (PhII And PhIII)- 2013 Global Pharma Milestones in 2013 Roche: Breast Cancer Franchise And Actemra To Drive Near Term Growth, And Multiple Blockbusters In Pipeline To Take Care Of Long Term Growth GlaxoSmithKline: Next Generation Bronchodilators, Melanoma, Hiv And Emerging Market To Lead The Way While Regulatory Overhang In Respiratory And EU Pricing Pressure Persist Bristol-Myers Squibb: Pressures To Dominate In The Near Term, Pipeline Will Take Longer To Deliver AstraZeneca: 2013 Will Be A Transition Year And AZN May Have To Take Some Bold Initiatives Eli Lilly: Late Stage Pipeline Fickle And Risky Merck: News-flow from Mega-trial on MRK's cardiology Franchise would reshape Merck's Growth Prospects Novartis: Back on a Growth Trajectory Novo Nordisk: Hemophilia Franchise and Thrice Weekly Degludec – The Future Drivers Pfizer: M&A Only Can Drive Further Upside In The Near Term Sanofi: Solid Base Business, But Upside From Pipeline Will Take Longer To Come About Global Pharma Sector Industry Tables
  • provides valuations and an in depth analyses of biotech companies, their launched drug portfolio and promising drug candidates in the pipeline.
hamelinclara

Trius: In An About Face, Congress Is Helping Biotech Companies That Are Developing Anti... - 0 views

seekingalpha.com/...hat-are-developing-antibiotics

trius pharma US

shared by hamelinclara on 15 Jan 13 - No Cached
  • The implications for Trius (TSRX) and other leading biotechnology companies involved in antibiotics development are profound.
  • ost large pharmaceutical and biotechnology firms have avoided antibiotics for much of the past two decades in large part due to the intrusion of Congress into the regulatory process
  • The most visible sign of this shift in attitude came from Congress with the passage of the Generating Antibiotics Incentives Now Act or GAIN which became effective on October 1, 2012. This was intended to spur development of new antibiotics through streamlining a regulatory process which has been oppressive for much of the last decade. Responding to the prompting of Congress, I expect the FDA to approach regulatory approval of new antibiotics with the same sense of urgency as drugs for cancer. The end result will be quicker approval of new drugs and new indications for existing antibiotics.
  • ...3 more annotations...
  • Antibiotics were major drivers of sales growth for the pharmaceutical industry in the 1970s, 1980s and early 1990s which caught the attention of the industry's many critics. A consensus developed among politicians, consumer groups and payors that there was no need for new antibiotics as most bacteria were susceptible to existing products. They saw new antibiotics as offering no advantages over existing drugs even though they were priced many times higher. Faced with this hostile environment, drug companies began to de-emphasize antibiotic research and focus on trendy new areas like depression, cholesterol lowering, gastrointestinal reflux disease, etc.
  • Adding to the move away from antibiotic development was considerable scrutiny about side effects that the industry came under in the early part of the 2000s. A major catalyst for this was the Vioxx side effect issues that caused Merck (MRK) to withdraw this anti-inflammatory drug from the market in 2004
  • ooking beyond the GAIN Act, infectious disease experts, FDA and industry are working on proposals for a new restricted approval pathway that would speed the development of new antibacterial drugs and could address some of the economic disincentives that have driven most pharma companies out of the space. A drug's safety and effectiveness would be studied in substantially smaller, more rapid, and less expensive clinical trials, like those typically used to support Orphan Drug approvals. They would be narrowly indicated for use in small, well-defined populations of patients for whom the drugs' benefits have been shown to outweigh their risks. It would slash the number of patients required to gain approval from about 1,400 for the typical antibiotic indication to 100 or less, cut development time in half, and reduce regulatory uncertainty
1 - 4 of 4
Showing 20▼ items per page